Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
ipilimumab fda approval history | 1.75 | 1 | 4151 | 84 | 31 |
ipilimumab | 0.79 | 0.4 | 9579 | 69 | 10 |
fda | 1.55 | 0.7 | 5846 | 75 | 3 |
approval | 1.47 | 0.9 | 4036 | 19 | 8 |
history | 1.81 | 0.6 | 1112 | 46 | 7 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
ipilimumab fda approval history | 1.44 | 0.4 | 468 | 53 |
ipilimumab nivolumab combination fda approval | 1.72 | 0.5 | 39 | 47 |
ipilimumab and fda indications | 0.53 | 0.8 | 1042 | 69 |
history of ipilimumab in melanoma treatment | 0.44 | 0.1 | 2113 | 89 |
golimumab fda approval history | 0.64 | 0.9 | 8843 | 57 |
cemiplimab fda approval history | 2 | 0.5 | 8481 | 52 |
adalimumab fda approval history | 0.06 | 0.3 | 8616 | 14 |
ipilimumab product monograph canada | 1.57 | 0.2 | 3778 | 17 |
ipilimumab cancer research uk | 1.49 | 1 | 4533 | 65 |
ipilimumab patent expiry date | 2 | 0.2 | 7663 | 13 |
ipilimumab cost in india | 0.34 | 1 | 108 | 21 |
nivolumab ipilimumab nsclc fda | 1.7 | 0.6 | 5936 | 7 |
ipilimumab + nivolumab | 1.05 | 0.2 | 1172 | 79 |
ipilimumab failed indications due to safety | 0.16 | 0.1 | 6409 | 47 |
injection ipilimumab 1 mg | 0.37 | 1 | 5144 | 2 |
ipilimumab cost per dose | 1.54 | 1 | 4616 | 82 |
cpt code for ipilimumab | 1.08 | 1 | 8941 | 43 |
ipilimumab and nivolumab macmillan | 0.09 | 0.3 | 7203 | 27 |
nivolumab/ipilimumab | 0.12 | 0.8 | 1581 | 39 |
ipilimumab and nivolumab patient information | 1.29 | 0.5 | 1965 | 18 |
ipilimumab and nivolumab drug class | 0.85 | 0.3 | 6231 | 88 |